Profound Medical Corp. (PROF) stock

PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$7.85+0.17 (+2.21%)

Close on Nov 11, 2026Market cap $286.78MP/E –Yield –

Profound Medical ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2023 it was -$27.51M. The highest annual figure on record is -$13.39M in fiscal 2019.

Period	Period end	Value	Change
FY2023	Dec 31, 2023	-$27.51M	–
FY2022	Dec 31, 2022	-$30.52M	–
FY2021	Dec 31, 2021	-$28.41M	–
FY2020	Dec 31, 2020	-$17.33M	–
FY2019	Dec 31, 2019	-$13.39M	–

Parsed from the XBRL in Profound Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PROF.

Revenue growth65.3% · median -25.9%

Gross margin73.9% · median 44.2%

Operating margin-145.1% · median -39.5%

Net margin-137.5% · median -16.2%

Advertisement
300 × 250

See a number that looks wrong?